AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced $36 million in series B funding, bringing its total funding to $71 million. The round, which included investments from F-Prime Capital, JAZZ Venture Partners, Sway Ventures and SVB Ventures, set up AppliedVR for rapid growth as it prepares for its decision from the FDA on its first de novo submission.

Led by co-founders Matthew Stoudt and Josh Sackman, AppliedVR is a leader in immersive therapeutics, pioneering virtual reality-based treatments that address the complexity of pain and other conditions. Rooted in a science-backed, clinically validated program, the company's flagship immersive therapeutic device3 for chronic pain is the first VR-based prescription therapeutic to receive FDA Breakthrough Device Designation. Offering a comprehensive approach that addresses multiple pain indicators, the solution enables patients to change the way they process pain and develop new, positive habits and coping skills that improve quality of life. Founded in 2015, AppliedVR is headquartered in Los Angeles and was recently named a 2021 Fast Company Most Innovative Company.